Polymeric Microparticle Depot for Sustained Intra-articular Protein Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sustained release pharmaceutical compositions for intra-articular administration of therapeutic proteins, such as those for osteoarthritis, face challenges in achieving long-term benefits due to rapid clearance from the joint, leading to insufficient drug levels and limited impact on disease progression.
Innovation Solution
A pharmaceutical composition comprising a triblock copolymer and a diblock copolymer, combined with an Interleukin-1 antagonist therapeutic protein, an organic solvent, and optional stabilizers, which forms a depot upon injection, providing sustained release and controlled degradation for extended protein delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If free drugs are injected intra-articularly, then immediate drug availability is achieved, but rapid clearance occurs over a period not exceeding a few hours resulting in poor and insufficient drug levels
Solution Approach 1:
The patent applies preliminary action by pre-formulating therapeutic proteins within polymeric microparticles before injection. The proteins are encapsulated in advance, allowing them to be released gradually at the injection site rather than being cleared rapidly as free drugs. This pre-prepared controlled release system ensures sustained drug levels over extended periods while maintaining immediate availability through the injection process itself.
Solution Approach 2:
The patent uses polymeric microparticles as an intermediary carrier between the therapeutic protein and the intra-articular space. These microparticles serve as a mediator that protects the protein from rapid clearance by lymphatic drainage while enabling controlled release. The microparticle formulation acts as an intermediate structure that bridges the gap between immediate drug availability and sustained duration of action.
2Duration of action of moving object
If sustained release formulations are used, then extended drug delivery is achieved, but limited long-term benefits are observed and arthritis progression is not prevented
Solution Approach 1:
The patent applies parameter changes by modifying the polymeric microparticle formulation parameters to optimize protein release kinetics and stability. By adjusting microparticle composition, size, and degradation characteristics, the formulation achieves both extended delivery duration and reliable therapeutic efficacy. The controlled release parameters are tuned to maintain effective drug levels long-term while preventing arthritis progression.
Solution Approach 2:
The patent uses composite materials by combining therapeutic proteins with polymeric microparticle matrices. This composite formulation integrates the benefits of sustained release polymers with the therapeutic activity of proteins, creating a system that provides both extended delivery duration and reliable disease-modifying effects. The composite structure enables long-term benefits and prevents arthritis progression more effectively than free protein administration.
3Ease of operation
If therapeutic proteins are administered intra-articularly, then local treatment is achieved, but efficient lymphatic drainage causes quick clearance and retrieval in the systemic compartment
Solution Approach 1:
The patent uses polymeric microparticles as an intermediary carrier that intercepts the therapeutic protein before it can be cleared by lymphatic drainage. The microparticles serve as a protective intermediary structure that retains the protein at the injection site, preventing rapid loss through lymphatic channels while maintaining easy local administration through simple injection of the formulated product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves prolonged protein release over weeks or months, maintaining effective drug levels and reducing lymphatic clearance, thereby enhancing therapeutic efficacy and preventing arthritis progression.
Implementation Method 1
which forms a depot upon injection, providing sustained release and controlled degradation for extended protein delivery
Implementation Method 2
providing sustained release and controlled degradation for extended protein delivery
Implementation Method 3
providing sustained release and controlled degradation for extended protein delivery
Implementation Method 4
maintaining effective drug levels and reducing lymphatic clearance
Data Source
AI summary
The present invention provides a pharmaceutical composition comprising(a) a triblock copolymer having the formula:Av-Bw-Ax wherein A is a polyester, B is polyethylene glycol, v and x are the number of repeat units ranging from 1 to 3,000 and w is the number of repeat units ranging from 3 to 300 and v=x or v≠x in an amount of from about 3 to 25 w/w % of the total composition;(b) a diblock copolymer having the formula:Cy-Az Wherein A is a polyester, C is an end-capped polyethylene glycol and y and z are the number of repeat units with y ranging from 2 to 250 and z ranging from 1 to 3,000 in an amount of from about 3 to 35 w/w % of the total composition;(c) a therapeutic protein which is an Interleukin-1 antagonist in an amount of from about 0.5 to 25 w/w % of the total composition;(d) optionally one or more stabilizer compounds in an amount of from about 0.25 to 15 w/w % of the total composition; and(e) organic solvent in an amount of from about 50 to 80 w/w % of the total composition.